Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Verinata Health Inc. maintains a company patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 1 pending office action. This 1 action is being processed by a distinct examiner within a distinct art unit, which indicates a highly focused prosecution environment.
PULLIAM, JOSEPH CONSTANTINE is identified as the busiest examiner for this portfolio, with 1 pending office action under review. This examiner is responsible for the total active workload of the portfolio. For a practitioner, this means that all current patent office interactions are consolidated under a sole individual within the Biotechnology & Pharmaceuticals sector.
The use of a distinct art unit suggests that the pending matters involve a specific technical niche. Practitioners should focus their strategy on the specific examination patterns of PULLIAM, JOSEPH CONSTANTINE. Since the busiest examiner pending count matches the total number of pending office actions, the practitioner can ensure a consistent and unified approach to the pending intellectual property.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PULLIAM, JOSEPH CONSTANTINE | 1 | 38.5% | +33.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17871853 | USING CELL-FREE DNA FRAGMENT SIZE TO DETERMINE COPY NUMBER VARIATIONS | PULLIAM, JOSEPH CONSTANTINE | 17d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17871853 | USING CELL-FREE DNA FRAGMENT SIZE TO DETERMINE COPY NUMBER VARIATIONS | PULLIAM, JOSEPH CONSTANTINE | 17d overdue |
| Art Unit | Apps |
|---|---|
| 1687 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17871853 | USING CELL-FREE DNA FRAGMENT SIZE TO DETERMINE COPY NUMBER VARIATIONS | PULLIAM, JOSEPH CONSTANTINE | 1687 | §101§103 | Final Rejection | 17d overdue | Pending | Jul 22, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVerinata Health Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Joseph Constantine Pulliam has the most, with 1 of Verinata Health Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.